Join me today as I share updates and trading ideas in the
Market Master’s trading room
(you can access this for free right now!)
I am so fired up today, I can’t wait to start trading this morning! 🔥
With markets continuing to make new all-time highs seemingly every day, it has been one of the better trading environments I have seen in a long time.
While I’ve been having a lot of success with bigger stocks that have options, I have been landing on some of the biggest small-cap movers as well.
The thing is, solid trading patterns tend to work on stocks no matter how big or small they are.
I want to share that with you today. It is a stock that has been one of the biggest winners this year, and I think today is a very important time to look at it again.
Go to your favorite platform and pull up MAIA Biotechnology (MAIA) right now.
I know I have talked about this one several times this year already, but can you blame me?
MAIA has delivered phenomenal results for people who listened to me early on. It has literally been one of the hottest stocks in the entire market this year, gaining over 190% since the start of the year (so far!).
Even with this huge move, I still don’t think many know about it.
MAIA got a little “overheated” around a month ago when the stock doubled in price over a few weeks and spiked to nearly $6.
The thing with momentum stocks like this is that they tend to bounce back; the only question is when?
Well, yesterday might have given us a good clue about a possible reversal.
While the trading has arguably been boring the last month as MAIA has consolidated from this recent pullback, I want you to focus on yesterday’s trading that I highlighted below…
You’ll see that MAIA had a big drop in the morning that broke the trendline once again.
But here is what really caught my attention – buyers finally returned to buy up that dip and push it back above the trendline again to end the day.
That is one of the best reversal signals I can think of.
When a stock is up nearly 200% on the year, there are obviously a lot of traders who like it and are waiting for the right opportunity to get back in.
I think we could be seeing that moment right now with MAIA.
Of course, I would seriously consider my stop loss on a trade like this under $3, since that is where the panic selling took it yesterday. If the stock trades back below that level, I would say it just isn’t ready to run again.
On the upside, there are so many levels to consider.
I would really like to see the $3.50 start to act as support again, and then I think MAIA’s first upside target would be in the low $4 range.
That is where it traded a lot of volume in early June after the dip.
If MAIA can break through that low $4 level, I don’t see why it can’t retest the high it made near $6 at some point.
With yesterday’s reversal signal, I expect MAIA to be in play with many traders now.
Make sure you keep MAIA at the very top of your watchlist today.
Spend some time and do your homework on this today, and make sure you are watching it all day long. But I’ve included some background here…
MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company exploring genuinely groundbreaking cancer treatments.
Its lead asset — called THIO — “is the only direct telomere targeting agent currently in clinical development.”
Its action in cancer treatment has been featured in renowned publications such as Cancer Cell and Nature.
Here’s how it works…
There’s an enzyme called telomerase that’s present in 85% to 90% of human cancers and that “contributes significantly to the proliferation and reproductive immortality of cancer cells.”
According to the company, “THIO is recognized by telomerase and incorporated into telomeres in cancer cells. Once incorporated, THIO compromises the telomere structure and function, leading to ‘uncapping’ of the chromosome ends and thus resulting in rapid tumor cell death.”
On top of killing the cancer cells directly, THIO — coupled with an immune checkpoint inhibitor — seems to produce an immune memory specific to cancer cells “where the immune system [continues] to be active against the cancer cells after extended periods of time, with no additional treatment.”
If you know anything about cancer, you know that maintaining remission is the truly critical part of therapy, and THIO is showing promise in that respect.
On February 22, MAIA announced the completed enrollment of its Phase 2 clinical trial for THIO in cases of non-small cell lung cancer (NSCLC), noting that “preliminary data has demonstrated unprecedented rates of disease control and response to date.”
And on June 4, the company revealed new data on the trial, including a favorable overall response rate of 38% and a disease control rate of 85%.
MAIA CEO Vlad Vitoc said, “All exceptional measures of efficacy in our trial to date have exceeded our own expectations and outperformed standard of care treatments.”
He added that the data “advances THIO’s excellent clinical profile as a strong, safe, and highly effective alternative for patients who progressed following chemotherapy and other available treatments. We eagerly anticipate full efficacy data from THIO-101 in the second half of this year.”
MAIA notes that NSCLC is “the largest tumor type globally by mortality (1.7 million deaths annually) and dollar sales ($34 billion annually).”
But it appears that THIO may have applications well beyond NSCLC…
For instance, it has been granted three Orphan Drug Designations (ODD) by the FDA for “hepatocellular carcinoma (the dominant histology of primary liver cancers, ~90%), small cell lung cancer (the deadliest type of lung cancer), and malignant gliomas (the deadliest group of brain cancers, including glioblastomas).”
These designations afford the company seven years of U.S. market exclusivity after drug approval and tax credits for qualified clinical testing.
In an upcoming second clinical trial, MAIA will be pitting THIO against the likes of small cell lung cancer, liver cancer, and colorectal cancer.
On top of all this, MAIA is developing a second generation of THIO-derived drugs. They’ve advanced more than 80 to date, with three U.S. patent applications.
According to the company, “Preclinical studies of several of these agents have shown highly significant anti-cancer efficacy at low dose levels in multiple in vivo and in vitro models.”
For a more detailed breakdown of MAIA’s trial progress and drug pipeline, check out this press release that the company put out on June 6 detailing year-to-date progress.
In March, the company did a $2.9 million private placement, and five of the company’s independent directors participated, with two of them each purchasing $200,000 worth of shares.
One of those directors purchased an additional $300,000 worth of shares the following month, even after the stock price had more than doubled.
As CEO Vlad Vitoc noted, the directors’ investments “point to their confidence in the science and clinical pathways for our immuno-oncology therapies targeting difficult-to-treat cancers.”
Spend time right now doing your own research on the stock, and of course, always approach your trading in a responsible manner. Trading is very risky, and nothing is ever guaranteed, so never trade with more than you can afford to lose. Please read the full disclaimer at the bottom of this email as well so you are aware of additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.
Bottom line: I love finding stocks that have made huge moves and pulled back to key support levels. MAIA is one of the market’s strongest stocks this year, and I think it is only a matter of time before we see the uptrend resume higher again.
I think today is the day you need to get MAIA back on your radar.
To Your Success,
Jeff Bishop
P.S. Make sure you join me and over 1000 traders in the Market Master’s trading room today for live trading signals and education. You can access it at no cost right now.
*Just so you know, what you’re reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let’s be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren’t what you’d call “typical.”
Just a quick heads up about this ad you’re reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we currently have received twenty-five thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on July 9, 2024. Previously, we received fifteen thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on June 13, 2024. Previously, we received twelve thousand five hundred dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on June 7, 2024. Also, we were paid fifteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising MAIA Biotechnology, Inc for a one day marketing program on March 6, 2024. We were also previously paid fourteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising MAIA Biotechnology, Inc from a period beginning on November 15 through November 18, 2023, and also fifteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising MAIA Biotechnology, Inc from a period beginning on October 12 through October 13, 2023. These amounts were paid by someone else not connected to MAIA Biotechnology, Inc. It might be obvious, but whoever paid for this might own shares and is likely looking to sell some or all of them at any time after we send out this information, which might affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case.
Now, diving right into MAIA Biotechnology, Inc might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there’s exceptional risk involved in trading. This isn’t small potatoes we’re talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We’re shining a light on the good stuff about the company here, but it’s on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.
Oh, that brings us to another crucial point—we’re not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.
Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can’t wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who’s licensed to give you real advice. To be clear,
Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1ties br0ker-dealer, br0ker, 1nvestment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry authority, or any self-regulat0ry organization.
So, that’s the scoop! If you’re intrigued and want to learn more about the companies we talk about, hit up the SEC’s website to dig into their filings and see the full picture.